Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 209,631 shares of the medical research company's stock after selling 7,240 shares during the quarter. Toronto Dominion Bank owned about 0.05% of Thermo Fisher Scientific worth $109,054,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cypress Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $253,000. Intact Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after buying an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth $1,121,000. Clear Harbor Asset Management LLC raised its position in Thermo Fisher Scientific by 10.4% in the 4th quarter. Clear Harbor Asset Management LLC now owns 13,418 shares of the medical research company's stock worth $6,981,000 after purchasing an additional 1,269 shares during the period. Finally, Fifth Third Bancorp boosted its stake in shares of Thermo Fisher Scientific by 11.6% during the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock valued at $174,305,000 after purchasing an additional 34,917 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on TMO. Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock worth $7,305,942 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 0.1%

Thermo Fisher Scientific stock traded down $0.45 during mid-day trading on Tuesday, hitting $413.47. The company's stock had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. The company has a 50 day moving average of $449.99 and a 200-day moving average of $508.22. The stock has a market cap of $156.08 billion, a PE ratio of 25.01, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period in the prior year, the business earned $5.11 EPS. The business's revenue for the quarter was up .2% compared to the same quarter last year. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.